Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Oncology in Practice
  3. Anti-Cancer Agents and Biological Therapy
  4. Targeting NTRK Gene Fusions
  5. Overview of Cancers with NTRK Gene Fusion

NTRK Gene Fusions as Oncogenic Drivers

Overview of Cancers With NTRK Gene Fusion

Previous Page Next Page

NTRK gene fusions are oncogenic drivers and the resultant TRK fusion protein is a treatment target across many tumour types. The following section describes the various mechanisms of TRK activation in cancer, what NTRK gene fusions are, including how they are formed and their resulting activity, and the epidemiology of NTRK gene fusions.

NTRK Gene Fusions
Epidemiology of Cancers With NTRK Gene Fusion
Mechanisms of TRK Protein Activation in Cancer

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.